AGC Biologics to manufacture first FDA approved gene therapy for metachromatic leukodystrophy

The U.S. Food and Drug Administration has cleared AGC Biologics’ Milan site to begin manufacturing of Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel), a gene therapy for early-onset metachromatic leukodystrophy (MLD).

READ THE STORY at BioPharma »